Alternatives to FamGenix: a 2026 field guide for clinical pedigree software

Looking for an alternative to FamGenix? Here's an honest field guide. FamGenix is a genuinely strong clinical product, particularly for hereditary cancer risk assessment — it runs BOADICEA v6, Tyrer-Cuzick v8, Gail, Claus, and QRISK3 simultaneously from a single pedigree, offers a free Individual tier, and publishes tiered pricing. That combination is hard to beat in the cancer-risk niche. Most teams who reach this page are not looking to replace FamGenix because it is failing; they are looking to evaluate it against peers for workflows that extend beyond cancer risk, or to add capabilities (AI interpretation, programmatic access, broader disease coverage) that FamGenix does not currently offer.

This page covers four serious alternatives — TrakGene, Phenotips, Progeny, and Evagene. We are honest about where FamGenix is better: no alternative listed here matches it on cancer-risk breadth. We are equally honest about where each alternative is better: broader clinical scope, AI interpretation, programmatic platform access, or HPO phenotyping depth, depending on the alternative. Evagene publishes this site; we mark its gaps (BOADICEA, Tyrer-Cuzick, published pricing) as plainly as its strengths.

Short version. For cancer-risk-only practice, stay with FamGenix — its model breadth leads the category. For broader clinical genetics with AI and API surfaces, Evagene. For HPO-driven rare disease, Phenotips. For established FHIR-integrated enterprise use, TrakGene. For continuity with legacy enterprise clinical genetics, Progeny.

Why teams look for alternatives to FamGenix

The main reason is scope. FamGenix concentrates on hereditary cancer risk, which is exactly why its model breadth is so strong. Services whose work extends into cardiac genetics, reproductive genetics, rare disease diagnostics, or general Mendelian inheritance often need a broader clinical platform. They may continue to use FamGenix for cancer risk and add another tool for the rest — but one consolidated platform is usually preferred.

The second reason is modern workflow surface. AI-assisted clinical interpretation, REST APIs, webhooks, Model Context Protocol agents, and embeddable pedigree viewers are not among FamGenix's advertised features in 2026. Services building patient portals, EHR integration layers, AI agents, or internal tools often find another platform's programmatic surface more fit-for-purpose. A third reason, less common, is a preference for cloud-first architecture and a modern interaction model — FamGenix is a clinical product rather than a platform, and some teams want a platform.

Four alternatives worth evaluating

TrakGene

TrakGene is a clinician-built clinical genetics platform with HL7 FHIR-first integration and a public customer list including NIH, NHS services, and Geisinger. It is a broader clinical genetics platform than FamGenix and is particularly strong where EHR integration matters.

Where TrakGene fits as a FamGenix alternative: services that need FHIR-native EHR integration alongside pedigree work. Where it falls short: TrakGene does not publicly advertise BOADICEA v6 or Tyrer-Cuzick v8; if cancer-risk model breadth is the reason you chose FamGenix, TrakGene will not match it. Public pricing is not available, so procurement is heavier than FamGenix's published tiers.

Phenotips

Phenotips is an enterprise Genomic Health Record platform with the Human Phenotype Ontology (HPO) at its core. With 100,000+ records across 60+ countries per its homepage, it is well-established in rare disease diagnostics and phenotype-driven gene suggestion.

Where Phenotips fits as a FamGenix alternative: services whose work centres on undiagnosed rare disease and HPO phenotyping. Where it falls short: Phenotips is not positioned as a hereditary cancer risk platform and does not publicly enumerate the cancer risk models it runs. Enterprise sales-led procurement removes the lightweight evaluation path FamGenix offers via its free Individual tier. If your FamGenix use is cancer-focused, Phenotips is not the natural alternative.

Progeny

Progeny is one of the longest-running clinical pedigree vendors (product history reaching back to 1996), with a broad clinical genetics suite, research cohort tooling, and EHR integration. Its strengths are longevity, proven deployments, and a mature feature set.

Where Progeny fits: institutions that want a vendor with decades of clinical footprint and that need cohort-management features. Where it falls short relative to FamGenix: third-party reports cite rising pricing and an architectural heritage that predates modern cloud patterns. FamGenix's published pricing and free tier are a more accessible evaluation path than Progeny's enterprise sales cycle.

Evagene

Evagene is a modern, browser-first clinical pedigree platform. Clinically it covers gesture-driven pedigree drawing with NSGC/ISCN notation, a 200+ disease catalogue annotated with ICD-10 and OMIM, BRCAPRO, MMRpro, and PancPRO from the BayesMendel suite, Mendelian inheritance calculators for AD, AR, and XR conditions, batch risk screening across the disease catalogue, a karyogram viewer, and consanguinity detection via Wright's coefficient.

Where Evagene differs from FamGenix: a broader clinical scope (rare disease, Mendelian, consanguinity, cardiogenetic conditions through its catalogue), and a modern platform surface. AI clinical interpretation uses bring-your-own-key (BYOK) LLMs for Anthropic Claude and OpenAI GPT, so clinical text goes directly to your own LLM contract. Analysis Templates codify a house style for AI-drafted reports. The MCP server exposes 11 pedigree tools to Claude Desktop and Claude Code. A scoped REST API, HMAC-SHA256 webhooks, and the embeddable pedigree viewer (iframe/SVG/JS) open the product to integration in ways FamGenix does not advertise. Data interoperability includes GEDCOM 5.5.1, JSON, 23andMe, XEG, and pedigree image OCR.

Where Evagene falls short against FamGenix: it does not currently include BOADICEA v6 or Tyrer-Cuzick v8, and its cancer-risk set — BRCAPRO, MMRpro, PancPRO — is narrower than FamGenix's breadth. Pricing is not yet published (Evagene is in Alpha with free access via waiting list), so direct price comparison with FamGenix's tiers is not possible today. For services whose work is dominated by breast and ovarian risk assessment, FamGenix's cancer-risk set is a genuine advantage. For services whose work is broader and that want AI and programmatic access alongside cancer risk, Evagene is the intended fit.

Feature comparison matrix

Compiled from publicly available product pages as of April 2026. "—" means not publicly advertised.

How to choose

Cancer-risk-only practice. Stay with FamGenix. No listed alternative matches BOADICEA v6 + Tyrer-Cuzick v8 + Gail + Claus + QRISK3 simultaneously today.

Balanced clinical genetics with cancer plus Mendelian and rare disease. Evagene — BRCAPRO/MMRpro/PancPRO plus Mendelian calculators, batch screening across 200+ diseases, AI interpretation, and programmatic access. Accept the current BOADICEA/Tyrer-Cuzick gap.

HPO-first rare disease. Phenotips. HPO depth is its defining feature.

Modern FHIR-native platform. TrakGene if FHIR is non-negotiable; Evagene for generic REST-API-style integration.

Established enterprise continuity. Progeny retains institutional trust for long-horizon deployments.

Frequently asked questions

Further reading

• Hereditary cancer risk assessment
• Phenotips vs Evagene
• Progeny vs Evagene
• Clinical genetics pedigree tools: a field guide
• Mendelian inheritance calculator
• Pedigree drawing software
• The Evagene platform layer (API, MCP, webhooks)